These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD; Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948 [TBL] [Abstract][Full Text] [Related]
7. [Experience in using an absorbed influenza chemical vaccine for the immunization of donors in producing anti-influenzal gamma-globulin]. Egorov PA; Isupov FG; Tuĭmedova RA; Afanas'eva GA; Lobanova AM Tr Inst Im Pastera; 1976; 47():163-6. PubMed ID: 80045 [No Abstract] [Full Text] [Related]
8. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Breiman RF; Brooks WA; Goswami D; Lagos R; Borja-Tabora C; Lanata CF; Londoño JA; Lum LC; Rappaport R; Razmpour A; Walker RE; Gruber WC; Forrest BD Vaccine; 2009 Sep; 27(40):5472-9. PubMed ID: 19616493 [TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with intranasal influenza vaccine in the United States. Vasu N; Ghaffari G; Craig ET; Craig TJ Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371 [TBL] [Abstract][Full Text] [Related]
10. [Immunogenic and reactogenic properties of inactivated influenza vaccine purified and concentrated by gradient centrifugation]. Malikova EV; Safonova LS; Zueva LP; Znakova GM Tr Inst Im Pastera; 1982; 57():122-3. PubMed ID: 6763376 [No Abstract] [Full Text] [Related]
11. Safety and efficacy of influenza vaccine in children. Goldstein LG Ann Pharmacother; 2003 Nov; 37(11):1712-5. PubMed ID: 14565808 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation data from experimental series on a killed influenza vaccine purified and concentrated by differential and density gradient centrifugation. II. The results of a study of the reactogenic properties of the vaccine]. Karpukhin GI; Popov IV; Malikova EV Tr Inst Im Pastera; 1976; 47():156-9. PubMed ID: 802567 [No Abstract] [Full Text] [Related]
13. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
14. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of an attenuated, live, bivalent, influenza vaccine in children. Burech DL; Koranyi KI; Haynes RE Ohio State Med J; 1976 Jul; 72(7):385-7. PubMed ID: 934582 [No Abstract] [Full Text] [Related]
16. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Van Kampen KR; Shi Z; Gao P; Zhang J; Foster KW; Chen DT; Marks D; Elmets CA; Tang DC Vaccine; 2005 Jan; 23(8):1029-36. PubMed ID: 15620476 [TBL] [Abstract][Full Text] [Related]